Immediate Impact
1 from Science/Nature 76 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Works of Jacky Créquit being referenced
Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer
2012
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Jacky Créquit | 302 | 224 | 47 | 17 | 361 | |
| M. Guirado | 237 | 190 | 27 | 24 | 336 | |
| Melissa A.L. Vyfhuis | 197 | 176 | 34 | 30 | 374 | |
| Jeffrey T. Yorio | 136 | 192 | 66 | 21 | 318 | |
| Humera Khurshid | 130 | 179 | 76 | 24 | 323 | |
| Carlo Barone | 193 | 203 | 64 | 20 | 381 | |
| Chen Chen | 144 | 276 | 63 | 17 | 382 | |
| Deepa Rangachari | 174 | 295 | 37 | 13 | 348 | |
| Maxime Frélaut | 109 | 275 | 33 | 22 | 367 | |
| Oskar Bergengren | 233 | 140 | 43 | 13 | 405 | |
| Athanasios Karampeazis | 219 | 240 | 24 | 26 | 310 |
All Works
Login with ORCID to disown or claim papers
Loading papers...